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Abstract 
Background: Aberrant STAT1 signaling is observed in human hepatocellular carcinoma (HCC) and has been associ-
ated with the modulation of cell proliferation and survival. However, the role of STAT1 signaling in HCC and its under-
lying mechanism remain elusive.
Methods: We transiently transfected pcDNA3.1-STAT1 and STAT1 siRNA into SMMC7721 and HepG2 cells. Western 
blot and qRT-PCR examined the expression of protein and RNA of target genes. Cell viability was assessed using MTT 
assay, and cell cycle and apoptosis were analyzed by flow cytometry.
Results: We found that STAT1 overexpression increased protein expression of p53 and Fbxw7, and downregulated 
the expression of cyclin A, cyclin D1, cyclin E, CDK2, Hes-1 and NF-κB p65. These changes led to growth inhibition and 
induced G0/G1 cell cycle arrest and apoptosis in SMMC7721 and HepG2 cells. Conversely, ablation of STAT1 had the 
opposite effect on p53, Fbxw7, Hes-1, NF-κB p65, cyclin A, cyclin D1, cyclin E and CDK2, and improved the viability of 
SMMC7721 and HepG2 cells.
Conclusions: Our data indicate that STAT1 exerts tumor-suppressive effects in hepatocarcinogenesis through induc-
tion of G0/G1 cell cycle arrest and apoptosis, and may provide a basis for the design of new therapies for the interven-
tion of HCC in the clinic.
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Background
Hepatocellular carcinoma (HCC) accounts for 80–90  % 
of liver cancers and is the eighth most commonly occur-
ring cancer in the world [1]. Epidemiological studies 
have revealed that cirrhosis with hepatitis virus infection 
is the most predominant risk factor for HCC develop-
ment [2]. Emerging lines of evidence indicate that aber-
rant activation of several signaling cascades, including 
the activator of transcription (Jak/STAT), epidermal 
growth factor receptor (EGFR), Ras/extracellular sig-
nal-regulated kinase (ERK), CDKN1C/P57, phospho-
inositol 3-kinase (PI3K)/mammalian target of rapamycin 
(mTOR) [3], Cyclooxygenase-2/Snail/E-cadherin, NF-κB 
[4–7] and HGF/cMET pathways [8, 9] contributes to 
the pathogenesis of HCC. Our previous study has indi-
cated that the mRNA and protein expression of STAT1 
were significantly downregulated in the HCC tumor tis-
sues compared to the normal tumor-adjacent tissues [10]. 
However, the mechanisms underlying the disruption of 
these critical pathways in the tumorigenesis of HCC are 
still not fully elucidated.
There is compelling evidence that STAT1 play an 
important role in promoting apoptotic cell death, and has 
been supported by the findings that growth inhibiting 
and pro-apoptotic activities of interferon-gamma (IFN-γ) 
are largely mediated by STAT1 signaling [11]. It has been 
observed that IFN-γinduce apoptotic sensitization of 
cells to various death signals such as TNF-α, Fas, TRAIL 
[12, 13]. Our previous study pointed out that STAT1 
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may inhibit HCC growth by regulating the p53-related 
cell cycling and apoptosis in HepG2 cell [10]. Increasing 
evidence now suggests that STAT1 signaling also medi-
ates non-apoptotic cell death, a category which includes 
necrotic and autophagic cell death. The mechanisms of 
non-apoptotic pathways, which often involves reactive 
oxygen species (ROS) and a caspase-independent path-
way. In addition, STAT1 pathway may play an important 
role in antiviral defense, inflammation, and injury in liver 
disease [14]. STAT1 is crucial for the control of hepatitis 
C virus (HCV) replication although the HCV core pro-
tein can selectively degrade STAT1, and subsequently 
subvert the Jak-STAT kinase [15]. It is possible that 
STAT1 negatively regulate the growth of HCC. However, 
how STAT1 regulates the growth of HCC has not been 
clarified.
In this present study, we tested the impact of induction 
or knockdown of STAT1 expression on the proliferation, 
apoptosis and cell cycle of HCC cell line SMMC7721 
and HepG2. We have demonstrated that STAT1 upreg-
ulation can significantly inhibit the in  vitro growth of 
SMMC7721 and HepG2. Conversely, STAT1 knockdown 
promoted proliferation in the same cell line. STAT1-
induced growth suppression is at least partially due to 
apoptosis and G0/G1 cell cycle arrest. Consistent with 
cell cycle arrest, expression levels of cyclin A, cyclin D1, 
cyclin E, and CDK2 protein all decreased. Upregulation 
of p53 and Fbxw7 expression and downregulation of 
NF-κB p65 and Hes-1 were observed, and may be related 
to STAT1-induced apoptosis. Therefore, Our data sug-
gest that STAT1 may be a negative regulator of the devel-
opment and progression of human HCC growth through 
induction of apoptosis and cell cycle arrest.
Results
STAT1 overexpression induces apoptosis and cell cycle 
arrest in SMMC7721 and HepG2 cells
SMMC7721 and HepG2 cells were engineered to tran-
siently express high levels of a recombinant plasmid 
encoding the STAT1 sequence (pcDNA3.1-STAT1) 
or control empty vector (EV) pcDNA3.1. The levels of 
STAT1 expression were determined by qRT-PCR and 
western blot assays. Compared with the control, the lev-
els of STAT1 proteins in the pcDNA3.1-STAT1-trans-
fected cells showed higher expression than that in the EV 
and unmanipulated cells (Fig. 1a). Similarly, the levels of 
STAT1 mRNA in the pcDNA3.1-STAT1-transfected cells 
were significantly higher than that in the EV and unma-
nipulated cells (Fig.  1b). The results of the MTT assay 
(Fig.  1c) indicate that overexpression of STAT1 caused 
growth inhibition in SMMC7721 and HepG2 cells. The 
pcDNA3.1-STAT1-transfected cells grew significantly 
more slowly than that in the EV and unmanipulated cells 
(P  <  0.05). We monitored apoptosis in cultured cells by 
staining them with Annexin V and Propidium Iodide 
(PI) for subsequent flow cytometry analysis. We found 
that apoptosis was more prevalent in pcDNA3.1-STAT1-
transfected cells than in EV (P  <  0.05) (Fig.  1d, f ). Fur-
thermore, flow cytometry analysis was used to measure 
the cell cycle distribution, as predicted, pcDNA3.1-
STAT1-transfected SMMC7721 and HepG2 cells showed 
a higher proportion of cells in G0/G1 phase (88.17 and 
90.87  %) compared with control EV cells (76.80 and 
77.27  %) (P  <  0.05), indicating that STAT1 significantly 
inhibited cell cycle progression (Fig.  1e, g), suggesting 
that STAT1 induces G0/G1 cell cycle arrest and apoptosis 
in SMMC7721 and HepG2 cells.
Knockdown of STAT1 expression activates proliferation 
of SMMC7721 and HepG2 cells
SMMC7721 and HepG2 cells were used to monitor cell 
survival and growth based on cell cycle and apoptosis after 
transfection with STAT1 siRNA or control siRNA. To test 
siRNAs efficiency, STAT1 transcript levels were evaluated 
by western blot and qRT-PCR assays. We found that all of 
the tested siRNA effectively reduced the levels of STAT1 
expression and transfection with the siRNA1, siRNA2, and 
siRNA3, resulted in inhibition of STAT1 expression by 
nearly 75, 86, and 65 % (Fig. 2a, b, c). MTT assay revealed 
that the ablation of STAT1 improved SMMC7721 and 
HepG2 cells viability, the STAT1 knockdown cells grow-
ing significantly faster than control siRNA-transfected or 
untreated cells (P < 0.05) (Fig. 2d). Flow cytometry analy-
sis was used to analyze the cell cycle and rate of apoptosis. 
The result showed that STAT1 knockdown lowered the 
rate of apoptosis in SMMC7721 and HepG2 cells (P < 0.05, 
Fig. 2e, g) compared with control siRNA-transfected cells 
(P < 0.05). STAT1 knockdown significantly increased the 
cell cycle progression. The percentage of G0/G1 phase in 
siRNA-transfected SMMC7721 and HepG2 STAT1 cells 
(72.61 and 76.38 %) was lower than that of control siRNA 
cells (80.65 and 84.31 %) (Fig. 2f, h).
STAT1 alters the expression of apoptosis‑related proteins 
in SMMC7721 and HepG2 cells
We analyzed the expression of apoptosis-related proteins 
p53, Fbxw7, Hes-1, and NF-κB p65 via western blot and 
qRT-PCR. Western blot analysis showed that transient 
pcDNA3.1-STAT1 induced a significant increase in p53 
and Fbxw7 expression in SMMC7721 and HepG2 cells 
(P  <  0.05, Fig.  3a, b, c), while the expression of Hes-1 
and NF-κB p65 were significantly decreased compared 
with SMMC7721, HepG2 and EV cells, (P < 0.05, Fig. 3a, 
d, e). We also monitored the mRNA expression of these 
proteins using qRT-PCR and obtained similar results 
(not shown). After transfection with STAT1 siRNA2 or 
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control siRNA, Hes-1 and NF-κB p65 expression were 
increased (Fig.  3f, i, j), whereas p53 and Fbxw7 were 
down-regulated in STAT1 siRNA2 cells compared with 
control siRNA-transfected cells (P < 0.05) (Fig. 3f, g, h).
STAT1 down‑regulates the expression of cyclin A, cyclin D1, 
cyclin E, CDK2 in SMMC7721 and HepG2 cells
Western blot analysis showed that 48  h after transient 
transfection with pcDNA3.1-STAT1, cyclin A, cyclin D1, 
Fig. 1 Effects of STAT1 overexpression on SMMC7721 and HepG2 cells growth. a, b SMMC7721 and HepG2 cells were transfected with an expres-
sion vector containing STAT1 and empty vector (EV), or they were left untreated, the levels of STAT1 expression were determined by qRT-PCR and 
western blot assays; c cell proliferation was quantified by MTT assay. STAT1-transfected SMMC7721 and HepG2 cells grew significantly more slowly 
than EV or untreated cells; d, f apoptosis was monitored by flow cytometry. The percentage of early apoptotic cells was quantified, and the frac-
tion of apoptotic STAT1-transfected SMMC7721 and HepG2 cells were higher than that of EV cells (P < 0.05); e, g cell cycle was monitored by flow 
cytometry. STAT1-transfected SMMC7721 and HepG2 cells showed a higher proportion of cells in G0/G1 phase (88.17 and 90.87 %) compared with 
control cells (76.80 and 77.27 %) (P < 0.05)
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Fig. 2 Effects of STAT1 knockdown on SMMC7721 and HepG2 cells growth. a, b, c qRT-PCR and western blot assays were used to determine siRNAs 
efficiency; d cell proliferation was quantified by MTT assay. STAT1 siRNA-transfected SMMC7721 and HepG2 cells grew significantly faster than 
control siRNA-transfected cells (P < 0.05); e, g apoptosis was detected by flow cytometry. The percentage of early apoptotic cells was quantified, 
and the fraction of apoptotic cells was lower in STAT1 siRNA2-transfected cells than in those transfected with control siRNA (P < 0.05); f, h STAT1 
knockdown significantly increased the cell cycle progression. The percentage of G0/G1 phase in STAT1 siRNA2 cells (72.61 and 76.38 %) was lower 
than that of control siRNA cells (80.65 and 84.31 %) (P < 0.05)
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cyclin E and CDK2 expression levels were significantly 
decreased (P  <  0.05, Fig.  4a, b, c, d, e), when compared 
with SMMC7721, HepG2 and EV cells. In contrast, cyc-
lin A, cyclin D1, cyclin E and CDK2 expression levels 
were significantly increased 48 h after transient transfec-
tion with STAT1 siRNA2 when compared with control 
siRNA-transfected cells (P  <  0.05, Fig.  4f, g, h, i, j). The 
mRNA expression of these proteins were consistent with 
those obtained by western blot (not shown).
Discussion
The signal transducers and activators of transcription 
(STATs) belong to a family of seven cytoplasmic pro-
teins that function as signal messengers and transcription 
factors participating in cellular responses to cytokines 
and growth factors [16, 17]. Among these proteins, the 
STAT1 plays a critical role in the regulation of diverse 
biological actions, including antiviral defense, induction 
of cell death, and growth arrest [18].
Fig. 3 Effect of STAT1 on p53, Fbxw7, Hes-1 and NF-κB p65. a, b, c, d, e Western blot was used to analyze p53, Fbxw7, Hes-1 and NF-κB p65 protein. 
Actin served as internal control. p53 and Fbxw7 were significantly increased, Hes-1 and NF-κB p65 were significantly decreased in STAT1-transfected 
SMMC7721 and HepG2 cells compared to SMMC7721, HepG2 and EV cells (P < 0.05); f, g, h, i, j showed p53, Fbxw7, Hes-1 and NF-κB p65 protein 
expression in STAT1 siRNA2, control siRNA, SMMC7721 and HepG2 cells. The protein of p53 and Fbxw7 were significantly decreased, Hes-1and NF-κB 
p65 were significantly increased in STAT1 siRNA2 cells compared to control siRNA, SMMC7721 and HepG2 cells (P < 0.05)
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In this study, we transiently transfected STAT1 expres-
sion vectors and STAT1-specific siRNA into SMMC7721 
and HepG2 cells to investigate the function of STAT1 in 
driving HCC development or progression. We observed 
that STAT1 overexpression caused growth inhibition, 
induced G0/G1 cell cycle arrest and promoted apopto-
sis in SMMC7721 and HepG2 cells, whereas ablation of 
STAT1 improved viability. The role of the STAT1 cas-
cade in tumor is controversial, and despite strong data 
indicating that STAT1 downregulation was most promi-
nent in the tumor cells themselves when compared with 
the surrounding stroma and infiltrating lymphocytes 
[19, 20]. Studies demonstrated that STAT1 controls anti-
tumorigenic effects in part by upregulation of caspases 
1, 2, 3, 7, and 8 [21], cyclin-dependent kinase inhibitor 
1A (CDKN1A) [22], IFN-regulatory Factor 1 (IRF1)/p53 
pathway [23], and down-regulation of B cell CLL/Lym-
phoma 2 (BCL2) family [24]. In contrast, other groups 
Fig. 4 Effect of STAT1 on cyclin A, cyclin D1, cyclin E and CDK2. a, b, c, d, e Western blot was used to analyze cyclin A, cyclin D1, cyclin E, and CDK2 
protein expression. Actin served as internal control. Cyclin A, cyclin D1, cyclin E, and CDK2 expression levels were significantly decreased in STAT1-
transfected SMMC7721 and HepG2 cells compared to SMMC7721, HepG2 and EV cells (P < 0.05); f, g, h, i, j cyclin A, cyclin D1, cyclin E, and CDK2 
protein were analyzed by western blot in STAT1 siRNA2, control siRNA, SMMC7721 and HepG2 cells. Cyclin A, cyclin D1, cyclin E and CDK2 expres-
sion levels were increased in STAT1 siRNA2 cells when compared with control siRNA, SMMC7721 and HepG2 cells (P < 0.05)
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have found that in certain cellular contexts the STAT1 
pathway may mediate tumor cell growth. Overexpression 
of the IFN/STAT1 pathway is associated with poor prog-
nosis in different types of cancer, and selected against 
fractionated ionizing radiation (IR) and IFN-resistant 
phenotype from a radiosensitive parental tumor SCC61 
[25–27].
Apoptosis and cell cycle arrest involve complex molec-
ular cascades, and dysfunction of various genes may lead 
to the onset and progression of apoptosis and cell cycle 
arrest. We explored the mechanism of STAT1-induced 
apoptosis and cell cycle arrest by assessing the effect 
of STAT1 on the expression of apoptosis-related fac-
tors (p53, Fbxw7, Hes-1, and NF-κB p65) and cell cycle 
regulators (cyclin A, cyclin D1, cyclin E, and CDK2) in 
SMMC7721 and HepG2 cells. It is well recognized that 
STAT1 promotes cell death through mechanisms that 
are dependent upon transcriptional activation of genes 
encoding proteins involved in modulating or promoting 
cell death, such as caspases, death receptors and ligands, 
iNOS, and Bcl-xL, as well as those involved in cell cycle 
arrest, such as p21 WAF1. It is also interesting to note 
that STAT1 can associate with proteins that are directly 
or indirectly involved in apoptotic cell death, including 
TRADD, p53, HATs and HDAC. Previous studies have 
demonstrated that overexpression of mutant or wild-
type p53 can result in apoptotic cell death and that p53 
can cause cell cycle arrest by transcriptionally upregulat-
ing p21 [28]. Fbxw7 is a key tumor suppressor that regu-
lates cell proliferation in different HCC cell lines. It has 
been shown that Fbxw7 is directly regulated by p53 [29]. 
High levels of Fbxw7 might decrease the pool of avail-
able cell cycle regulators (cyclin A, cyclin E), triggering 
arrest in G1 phase and accounting for low proliferation 
rates. NF-κB signaling has been recognized as the major 
pathway responsible for cytokine-associated cancer 
development, inactivation of NF-κB inhibits cell growth 
and induces intrinsic apoptosis in hepatocellular car-
cinoma cells [30]. Protein levels and kinase activities of 
cyclin A, cyclin D1, cyclin E and CDK4 are significantly 
elevated in HCC, and decreased levels of cyclin D1 have 
been correlated with growth inhibition and G0-G1 cell 
cycle arrest [31, 32]. Here, we found a similar effect with 
STAT1 modulation in HCC cell lines. Our results showed 
that upon transient expression of active STAT1 in 
SMMC7721 and HepG2 cells, p53 and Fbxw7 expression 
levels were increased, whereas cyclin A, cyclin D1, cyc-
lin E, CDK2, Hes-1 and NF-κB p65 were downregulated. 
STAT1 knockdown by siRNA caused downregulation of 
p53 and Fbxw7, and upregulation of cyclin A, cyclin D1, 
cyclin E, CDK2, Hes-1 and NF-κB p65. Taken together, 
our results suggest that STAT1 possibly induces G0-G1 
cell cycle arrest through a mechanism of downregulating 
cyclin A, cyclin D1, cyclin E, CDK2, and Fbxw7 synergiz-
ing with p53 to trigger apoptosis in vitro. To the best of 
our knowledge, our study provides the first evidence for 
STAT1-induced G0/G1 cell cycle arrest and apoptosis in 
SMMC7721 and HepG2 cells.
Conclusions
In summary, our data indicated that STAT1 may function 
as a suppressor of HCC cell proliferation, and a regulator 
of HCC cell apoptosis and cell cycle arrest. Hence, our 
findings may provide a basis for the design of new thera-
pies for the intervention of HCC in the clinic.
Methods
Cell culture and transfections
SMMC7721 and HepG2 cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 
10 % fetal calf serum at 37 °C and 5 % CO2. The plasmids 
of pcDNA3.1 (EV) and pcDNA3.1-STAT1 were obtained 
from GenePharma. pcDNA3.1 (EV) and pcDNA3.1-
STAT1 were transfected into SMMC7721 and HepG2 
cells at 70  % confluence using X-tremeGENE HP DNA 
transfection reagent (Roche, Mannheim, Germany) 
according to the manufacturer’s protocol. Cells were 
transfected for 48 h in 6-well plates and then analyzed for 
flow cytometry, MTT assay, western blot and qRT-PCR.
RNA interference (RNAi)
The sense and antisense sequences of the STAT1-specifc 
and control siRNAs were synthesized by GenePharma, 
Shanghai, China and are present in Table 1. SMMC7721 
and HepG2 cells (2 ×  105/well) were cultured in 6-well 
plates at 70  % confluence, and transfected in duplicate 
with 1.3 µg each type of STAT1-specific or control siRNA 
using X-tremeGENE siRNA transfection reagent (Roche, 
Mannheim, Germany) according to the manufacturer’s 
instructions. Cells were transfected for 48  h in 6-well 
plates and then analyzed for flow cytometry, MTT assay, 
western blot and qRT-PCR.
Cell cycle determination
After transfection with the corresponding STAT1 vectors 
or siRNAs for 48 h, the cells were harvested and washed 
twice with cold PBS, then fixed in 75 % alcohol for 2 h at 
4  °C. After washing in cold PBS three times, cells were 
resuspended in 1 mL of PBS solution with 40 μg of pro-
pidium iodide (Sigma) and 100 μg of RNase A (Sigma) for 
30 min at 37 °C and analyzed with the BD Accuri C6 sys-
tem (Becton–Dickinson, USA). The distribution of cells 
in different phases of the cell cycle was calculated using 
the Modifit LT software.
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Apoptosis analysis
After transfection for 48  h, the cells were harvested 
and washed three times with cold PBS. Cells were then 
resuspended in the staining buffer and stained using the 
Annexin V-FITC Apoptosis Assay Kit (Bestbio, Shanghai, 
China) according to the manufacturer’s instructions. The 
stained cells were analyzed by flow cytometry (BD FAC-
SAria, R&D, USA). Annexin V-positive and propidium 
iodide-negative cells were counted as apoptotic cells.
MTT assay
Cell viability was assessed using the MTT colorimetric 
assay (R&D, USA). SMMC7721 and HepG2 cells were 
seeded in 96-well plates at a density of 1 × 104 cells per 
well in 100 μL complete medium. After transfection 
with the corresponding plasmid vector or siRNA, 10 μL 
MTT solution (5 mg/mL) was added, and cells were incu-
bated for an additional 4 h. Subsequently, 100 µL of MTT 
solubilization buffer was added to the wells. Following 
a 10-min mixing period, the absorbance was analyzed 
at 570  nm using a microplate reader. The background 
absorbance at 690  nm was subtracted from the 570  nm 
measurement. Each experiment was performed in tripli-
cate, and the mean value was calculated.
Quantitative Real‑time reverse transcription‑polymerase 
chain reaction (qRT‑PCR)
Total RNA was isolated from cultured cells using Tri-
zol (Invitrogen, Carlsbad, California, USA) according 
to the manufacturer’s instructions. RNA concentration 
and purity were determined from absorbance meas-
ured at both 260 and 280  nm. RNA (1  μg) was reverse 
transcribed using the PrimeScript® First Strand cDNA 
Synthesis Kit (Takara, Dalian, China) and random oli-
godeoxynucleotide primers. PCR amplification was per-
formed in 20 μL reactions containing cDNA generated 
from 2 ng of the original RNA template, 400 nmol/L of 
each gene-specific forward and reverse primer, 10 μL of 
2 ×  SYBR® Premix Ex Taq™ II (Takara, Dalian, China), 
0.4 μL of ROX reference dye, and 6.0 μL of dH2O. Ampli-
fied signals were detected using the ABI PRISM 7300 
Real-Time PCR system (ABI, USA). The annealing tem-
perature was optimized using the temperature gradient 
program that is part of the ABI PRISM software. Experi-
ments were performed in duplicate. The relative target 
mRNA levels were determined using the 2ΔΔCt method. 
The primer sequences used are summarized in Table 1.
Western blot analysis
Protein concentrations were determined using the BCA 
Protein Assay (Pierce, USA) according to the manufac-
turer’s instructions. Samples containing equal amounts 
of protein (40 μg) were resolved by 10 % SDS-PAGE and 
transferred to nitrocellulose membranes. After block-
ing for 2 h at room temperature with TBS-T (0.1 M Tris, 
0.9 % NaCl, and 0.05 % Tween-20 at pH 7.5) containing 
5 % skim milk, and probed at 4 °C overnight with rabbit 
anti-STAT1 (1:2000, Bioworld Technology), rabbit anti-
p53 (1:400), rabbit anti-Fbxw7 (1:400), rabbit anti-cyclin 
A (1:400), rabbit anti-cyclin D1 (1:400), rabbit anti-cyclin 
E (1:400), rabbit anti-CDK2 (1:400) (Beijing Biosynthe-
sis Biotechnology Co, Beijing, China), rabbit anti-NF-κB 
p65 (1:2000), rabbit anti-Hes-1 (1:2000) (Cell Signaling 
Technology Inc., Boston, USA), and mouse anti-actin 
(1:8000). Proteins were detected by exposing the blots to 
X-ray film (Kodak).
Statistical analysis
SPSS version 17.0 software was used for all statisti-
cal analyses. All of the results are expressed as the 
mean  ±  SD. Statistical analysis was performed using 
standard two-way ANOVA for repeated measurements, 
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and the Χ2 test was used to analyze the flow cytometry 
data. P values less than 0.05 were considered statistically 
significant.
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